OncoMatch/Clinical Trials/NCT05615974
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Is NCT05615974 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LM101 and Toripalimab for malignant tumors.
Treatment: LM101 · Toripalimab · Rituximab — This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
have progressed on standard therapy
Cannot have received: investigational therapy directed at the same target
Subject has received prior investigational therapy directed at the same target therapy
Cannot have received: any anti-tumor treatment
Exception: within 21 days prior to the first dosing of LM-101
Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-101, including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.
Cannot have received: participation in other interventional clinical trial
Exception: within 21 days prior to the first dosing of LM-101
Subjects has participated in any other interventional clinical trial within 21 days prior to the first dosing of LM-101
Cannot have received: major surgery or interventional treatment
Exception: within 28 days prior to the first dosing of LM-101 (excluding tumor biopsy, puncture, etc.)
Subjects who received major surgery or interventional treatment within 28 days prior to the first dosing of LM-101 (excluding tumor biopsy, puncture, etc.)
Lab requirements
Blood counts
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Kidney function
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Liver function
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify